Monitor for future data readouts or patent developments from this collaboration, which could enhance Propanc’s IP portfolio ahead of its Phase 1b trial. However, no immediate financial or clinical catalyst is indicated.
Price Chart
Executive Summary
Propanc Biopharma announced a new multi-year research collaboration with the Universities of Jaén and Granada in Spain to evaluate a senescence-modulating compound and support recent patent applications related to fibrosis and cancer. This extends a long-standing partnership that has previously yielded multiple patents, publications, and academic recognitions.
Key Facts
- Propanc Biopharma (PPCB) entered into a multi-year Joint Research Collaboration Agreement with the Universities of Jaén (UJA) and Granada (UGR) in Spain.
- This is the fifth agreement between Propanc and the universities over 17 years, resulting in four patent families, five peer-reviewed publications, and academic awards.
- The research will focus on evaluating a senescence-modulating (anti-aging) compound to support fibrosis and cancer-related patent claims.
- The project will be led by Prof. Macarena Perán Quesada (UJA) and Prof. Juan Antonio Marchal Corrales (UGR), with two postdoctoral fellows conducting experiments.
- Propanc plans to advance its lead asset, PRP, into a Phase 1b First-In-Human study in advanced cancer patients in 2026.
Financial Impact
No financial terms disclosed; likely minimal near-term cost given academic collaboration structure.
Risk Factors
- No guaranteed outcomes from the research collaboration.
- Propanc remains pre-revenue with high dependence on future clinical trial results and funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261252 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $0.2800 | awaiting T+5 | — | $2.43 (+767.86%) |
Oct 5, 2026 22d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $2.43 (−394.61%) |
Sep 29, 2026 28d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $2.43 (+374.33%) |
Aug 18, 2026 10w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $2.43 (+109.48%) |
Jul 14, 2026 15w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $2.43 (+49.08%) |
May 19, 2026 23w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $2.43 (+21.20%) |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $2.43 (+42.94%) |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | $2.43 (+32.97%) |
Apr 21, 2026 27w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | $2.43 (−14.06%) |
Mar 24, 2026 31w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | $2.43 (−12.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers